- Home
- TLPH vs RSF Comparison
TLPH vs RSF Comparison
Compare TLPH & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.83
Company Overview
Basic Information| Metric | TLPH | RSF |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 61.4M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLPH | RSF |
|---|---|---|
| Price | $0.83 | $14.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 237.5K | 11.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $14.81 |
| 52 Week High | $1.57 | $16.23 |
Technical Indicators
Market Signals| Indicator | TLPH | RSF |
|---|---|---|
| Relative Strength Index (RSI) | 32.22 | 45.04 |
| Support Level | $0.76 | $14.35 |
| Resistance Level | $1.01 | $14.66 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 28.77 | 25.81 |
Price Performance
Historical Comparison TLPH
RSF
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.